PMID- 27350752
OWN - NLM
STAT- MEDLINE
DCOM- 20170221
LR  - 20221207
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 12
DP  - 2016
TI  - SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 
      diabetes: patient selection and perspectives.
PG  - 239-49
LID - 10.2147/VHRM.S83088 [doi]
AB  - Controversy exists regarding the selection of second-line therapy for patients 
      with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control 
      with metformin therapy alone. Newer pharmacologic treatments for T2DM include 
      glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 
      inhibitors. Both the classes of medication are efficacious, exhibit positive 
      effects on weight, and are associated with minimal risk of hypoglycemia. The 
      purpose of this review is to compare the clinical trial and real-world 
      effectiveness data of glucagon-like peptide-1 receptor agonists versus 
      sodium-glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, 
      cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM. 
      This review summarizes comparative evidence for providers who are determining 
      which of the two classes may be the most appropriate for a specific patient.
FAU - Gurgle, Holly E
AU  - Gurgle HE
AD  - Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake 
      City, UT, USA.
FAU - White, Karen
AU  - White K
AD  - Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake 
      City, UT, USA.
FAU - McAdam-Marx, Carrie
AU  - McAdam-Marx C
AD  - Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake 
      City, UT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160604
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Cardiovascular Diseases/etiology/prevention & control
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy/economics
MH  - Drug Costs
MH  - Drug Therapy, Combination
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/economics/*therapeutic use
MH  - Incretins/adverse effects/economics/*therapeutic use
MH  - Kidney Tubules, Proximal/*drug effects/metabolism
MH  - Patient Selection
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Weight Loss/drug effects
PMC - PMC4902150
OTO - NOTNLM
OT  - A1c
OT  - GLP-1 receptor agonist
OT  - SGLT2 inhibitor
OT  - adverse effect
OT  - type 2 diabetes mellitus
OT  - weight loss
EDAT- 2016/06/29 06:00
MHDA- 2017/02/22 06:00
PMCR- 2016/06/04
CRDT- 2016/06/29 06:00
PHST- 2016/06/29 06:00 [entrez]
PHST- 2016/06/29 06:00 [pubmed]
PHST- 2017/02/22 06:00 [medline]
PHST- 2016/06/04 00:00 [pmc-release]
AID - vhrm-12-239 [pii]
AID - 10.2147/VHRM.S83088 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2016 Jun 4;12:239-49. doi: 10.2147/VHRM.S83088. 
      eCollection 2016.